Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ(40) and Aβ(42) Peptides in Plasma

Recent advances in neuroimaging and cerebrospinal fluid (CSF) biomarker assays have provided evidence of a long preclinical stage of Alzheimer’s disease (AD). This period is being increasingly targeted for secondary prevention trials of new therapies. In this context, the interest of a noninvasive,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Alzheimers Dis
Autori principali: Pérez-Grijalba, Virginia, Fandos, Noelia, Canudas, Jesús, Insua, Daniel, Casabona, Diego, Lacosta, Ana M., Montañés, María, Pesini, Pedro, Sarasa, Manuel
Natura: Artigo
Lingua:Inglês
Pubblicazione: IOS Press 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5044780/
https://ncbi.nlm.nih.gov/pubmed/27567833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-160325
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi